Altimmune, Inc.ALTEarnings & Financial Report
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, vaccines, and peptide-based therapies. Its pipeline covers infectious disease prevention, liver disease treatments, and metabolic disorder therapies, serving global biopharmaceutical and healthcare markets while advancing candidates through clinical trials.
ALT Q4 FY2025 Key Financial Metrics
Revenue
$26.0K
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
420.0%
Altimmune, Inc. Q4 FY2025 Financial Summary
Altimmune, Inc. reported revenue of $26.0K (up 420.0% YoY) for Q4 FY2025, with a net profit of N/A (down 18.0% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $26.0K |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Altimmune, Inc. Annual Revenue by Year
Altimmune, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $41.0K).
Altimmune, Inc. Quarterly Revenue & Net Profit History
Altimmune, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $26.0K | +420.0% | N/A | N/A |
| Q3 FY2025 | $5.0K | +0.0% | $-19.0M | -380280.0% |
| Q2 FY2025 | $5.0K | +0.0% | $-22.1M | -442920.0% |
| Q1 FY2025 | $5.0K | +0.0% | $-19.6M | -391500.0% |
| Q4 FY2024 | $5.0K | -86.5% | N/A | N/A |
| Q3 FY2024 | $5.0K | -98.6% | $-22.8M | -456900.0% |
| Q2 FY2024 | $5.0K | -16.7% | $-24.6M | -492800.0% |
| Q1 FY2024 | $5.0K | -76.2% | $-24.4M | -487880.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5000 | $5000 | $5000 | $5000 | $5000 | $5000 | $5000 | $26000 |
| YoY Growth | -76.2% | -16.7% | -98.6% | -86.5% | 0.0% | 0.0% | 0.0% | 420.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $188.4M | $173.3M | $147.9M | $139.3M | $157.3M | $190.3M | $218.4M | $279.9M |
| Liabilities | $15.4M | $20.8M | $14.5M | $15.8M | $15.1M | $29.0M | $32.8M | $55.0M |
| Equity | $172.9M | $152.5M | $133.4M | $123.5M | $142.2M | $161.4M | $185.6M | $224.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-16.4M | $-18.1M | $-27.1M | $-79.8M | $-16.8M | $-19.4M | $-11.9M | $-67.5M |